AXGN · Axogen, Inc. · Insider Trading

The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $48.01 to $51.46 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2026.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.43 to $46.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $235,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

This reflects the number of restricted stock units that vested June 19, 2026.

This reflects the number of restricted stock units that vested June 19, 2026.

This reflects the number of restricted stock units that vested June 19, 2026.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

This reflects the number of restricted stock units that vested June 19, 2026.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

This reflects the number of restricted stock units that vested June 19, 2026.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

This reflects the number of restricted stock units that vested June 19, 2026.

This reflects the number of restricted stock units that vested June 19, 2026.

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.50 to $42.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 31, 2018.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $44.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.44 to $43.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.26 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.25 to $43.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 20, 2024.

All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026.

All shares of Axogen, Inc. common stock underlying the board of director stock option were fully vested on June 6, 2025.

This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.

This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.

This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.

This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.